This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

HIV disease resulting in other malignant neoplasms of lymphoid, haematopoietic and related tissue기타 악성 림프세망내피조직 신생물을 유발한 인체면역결핍바이러스병

Contents and key points
ItemDetails
A. Classification codesICD-10: B21.3 (HIV disease resulting in other malignant neoplasms of lymphoid, hematopoietic and related tissue) | Special Copayment Reduction: V103 (severe intractable disease, 5 years)
B. SynonymsHIV disease; HIV disease resulting in other malignant neoplasms of lymphoid, haematopoietic and related tissue; HIV-associated Hodgkin lymphoma; HIV-associated multiple myeloma
C. Adult onsetLikelihood of onset in adulthood: Very high — B21.3 includes lymphohematopoietic malignant neoplasms not specified in B21.0-B21.2 (Hodgkin lymphoma, multiple myeloma, etc.), and occurs mainly in adults with HIV infection.
1. HistoryIncreased risk of Hodgkin lymphoma in patients with HIV has been reported since the 1980s. Large cohort studies of HIV-associated Hodgkin lymphoma were conducted from 2008. The risk persists after ART as a non-AIDS-defining malignancy.
2. CausesHIV immunosuppression + EBV co-infection is key to the development of Hodgkin lymphoma. When immune recovery is incomplete, proliferation of Reed-Sternberg cells evades immune surveillance. HHV-8-associated multicentric Castleman disease is a precursor state of lymphoma development.
3. GeneticsHIV-associated Hodgkin lymphoma: EBV LMP1 expression, NF-κB activation, CD30 overexpression in Reed-Sternberg cells. Genetically similar to non-HIV Hodgkin lymphoma, but with a much higher EBV association (about 80-100%).
4. General epidemiologyThe risk of developing Hodgkin lymphoma in persons with HIV is 5 to 10 times that of the general population. Its relative importance has increased as a non-AIDS-defining malignancy after ART. Median age at diagnosis about 35-40s.
5. PathophysiologyHIV CD4 decline → EBV reactivation → NF-κB activation by EBV LMP1 in Reed-Sternberg cell precursors → cell proliferation and immune evasion. Risk increases in an atypical immune environment (partial CD4 recovery + residual immune dysregulation).
6. SymptomsLymphadenopathy (cervical, mediastinal, axillary), B symptoms (fever, night sweats, weight loss), pruritus, fatigue. Advanced stage (III/IV) is common. Cough and dyspnea due to mediastinal lymphadenopathy.
7. SignsPainless lymphadenopathy, splenomegaly, mediastinal widening (chest X-ray), elevated LDH and alkaline phosphatase, cytopenia (with bone marrow involvement).
8. ScreeningIn patients with HIV, when persistent painless lymphadenopathy or B symptoms occur, perform a biopsy to differentiate lymphoma. Stage with PET-CT.
9. DiagnosisLymph node biopsy (histologic type: mixed cellularity is most common), identification of Reed-Sternberg cells, EBV EBER ISH. Whole-body staging with PET-CT. Bone marrow biopsy. Cotswolds staging classification.
10. TreatmentABVD (Adriamycin·bleomycin·vinblastine·dacarbazine) ± rituximab (for lymphocyte-predominant type with CD20 positivity). Continue with concurrent ART. Caution for bleomycin pulmonary toxicity (synergistic with HIV pulmonary complications). Stanford V and BEACOPP are also alternatives.
11. PrognosisIn the ART era, the complete remission rate of HIV-associated Hodgkin lymphoma is about 70-80% and the 5-year survival rate is about 50-70%. Somewhat worse than non-HIV Hodgkin lymphoma, but the difference narrows when immune function has recovered with ART.
12. PreventionMaintain CD4 with ART. Monitor for EBV-related complications. Although it is a non-AIDS-defining malignancy, risk can be reduced by HIV suppression.
13. ReferencesOlszewski AJ et al. AIDS 2016 and 9 others

1. History

In ICD-10, B21.3 refers to HIV disease resulting in lymphohematopoietic malignant neoplasms not included in Burkitt lymphoma (B21.1) and other non-Hodgkin lymphoma (B21.2). A representative example is Hodgkin lymphoma (HL). Although Hodgkin lymphoma is not an AIDS-defining malignancy, its risk in persons with HIV is 5 to 15 times higher than in the general population, and its course is more aggressive.

The observation that Hodgkin lymphoma is increased in persons with HIV has been reported since the late 1980s. Interestingly, HIV-associated Hodgkin lymphoma showed a paradoxical pattern in which the incidence actually increased after the introduction of ART. This is explained by the hypothesis that, when CD4 counts partially recover after ART, abnormal immune stimulation of EBV-infected Reed-Sternberg precursor cells may occur during reconstitution of the immune response to EBV. In addition, multicentric Castleman disease (MCD) occurs in HIV + HHV-8 patients and is known as a precursor state that progresses to HHV-8-associated lymphoma. These various lymphohematopoietic malignant neoplasms make up the clinical category of B21.3.

In terms of treatment history, ABVD (Adriamycin-bleomycin-vinblastine-dacarbazine) chemotherapy has been applied as the standard for HIV-associated Hodgkin lymphoma. As concurrent use with ART was confirmed to be safe, treatment outcomes improved greatly, and recently brentuximab vedotin (anti-CD30 antibody-drug conjugate) has been used in relapsed/refractory Hodgkin lymphoma.


2. Causes

Immune dysregulation caused by EBV and HIV is centrally involved in the development of HIV-associated Hodgkin lymphoma. EBV reactivation is frequent in persons with HIV, and the risk that EBV-infected B cells transform into Reed-Sternberg cells increases. In Hodgkin lymphoma, dependence on CD4 count is weaker than in non-Hodgkin lymphoma, and it commonly occurs even in the CD4 range of 200-400/μL. Multicentric Castleman disease (MCD) arises from HHV-8 infection and is characterized by chronic systemic inflammation and IL-6 overproduction. MCD can progress to HHV-8-associated lymphoproliferative disorders (primary effusion lymphoma, KSHV-associated DLBCL) and is included in the B21.3 category. Multiple myeloma can also occur in persons with HIV, but its association with HIV is weaker than that of Hodgkin lymphoma or NHL, and it generally occurs as an aging-related underlying disease in patients with HIV who live long after ART.


3. Genetics

In HIV-associated Hodgkin lymphoma, Reed-Sternberg cells have a typical gene expression profile. EBV LMP1 (Latent Membrane Protein 1) mimics CD40 signaling and continuously activates the NF-κB pathway, maintaining the proliferation and survival of Reed-Sternberg cells. CD30 overexpression is a characteristic finding of Hodgkin lymphoma and is a treatment target. The EBV association of HIV-associated Hodgkin lymphoma is about 80-100%, much higher than that of non-HIV Hodgkin lymphoma (about 30-50%). This suggests that HIV-induced impairment of EBV immune surveillance contributes more to EBV-associated tumorigenesis. Regarding histologic type, the mixed cellularity type is more common in HIV-associated disease, and the nodular sclerosis type is more common in non-HIV Hodgkin lymphoma. These differences reflect the characteristics of the immune microenvironment in patients with HIV (Th2 bias, abnormal NK cell function).


4. General epidemiology

The risk of developing Hodgkin lymphoma in persons with HIV is 5 to 15 times higher than in the general population. The standardized incidence ratio (SIR) is about 5-10, with some variation by race, sex, and region. Since the introduction of ART, the incidence of Hodgkin lymphoma as a non-AIDS-defining cancer (NADC) has been relatively stable or even slightly increased. This is presumed to be because, as the number of patients with HIV who live long on ART increases, the period of exposure to long-term chronic immune activation and EBV infection lengthens. The median age at diagnosis is about 30-40s, and it is more frequent in men than in women.


5. Pathophysiology

The 'paradoxical' immune environment of HIV-induced immunosuppression and partial recovery contributes to the development of Hodgkin lymphoma. HIV infection impairs EBV-specific CD4+ Th1 cell and CD8+ CTL responses, making EBV immune surveillance insufficient. When CD4 counts partially recover after ART, an abnormal immune response to EBV-infected B cells (interaction with aberrantly activated Reed-Sternberg precursor cells) may permit clonal proliferation of EBV LMP1-expressing cells. Chronic immune activation due to chronic HIV infection and overexpression of Th2 cytokines such as IL-10 and IL-13 form a tumor microenvironment favorable to the development of Hodgkin lymphoma. In MCD, HHV-8-induced IL-6 overproduction causes continuous B-cell stimulation and lymphoid tissue enlargement, raising the risk of HHV-8-associated lymphoma.


6. Symptoms

In HIV-associated Hodgkin lymphoma, advanced stage (Ann Arbor III/IV) is very common, at about 70-80%. Main clinical symptoms: painless lymphadenopathy (cervical, axillary, inguinal, and intra-abdominal). B symptoms (fever ≥38°C, night sweats, weight loss of 10% or more within 6 months) accompany in about 80%. Pruritus is characteristic but does not occur in all patients. Splenomegaly; upper abdominal discomfort with liver involvement. Cough, dyspnea, and superior vena cava syndrome due to mediastinal lymphadenopathy. Bone marrow involvement (about 30-50%): anemia, thrombocytopenia, fatigue. In MCD, recurrent fever, lymphadenopathy, splenomegaly, weight loss, and skin rash occur, and symptoms repeatedly worsen and remit periodically.


7. Signs

Painless, rubbery lymphadenopathy, splenomegaly and hepatomegaly, and progressive weight loss are characteristic. Laboratory findings include cytopenia (with bone marrow involvement), elevated ESR and CRP, elevated alkaline phosphatase and LDH (with liver or bone marrow involvement), and decreased albumin. Chest X-ray or CT may show mediastinal widening (lymphadenopathy) and pleural effusion. On PET-CT, increased FDG uptake in systemic lymph nodes and extranodal lesions is characteristic. Blood EBV DNA levels may be elevated. The CD4+ T-cell count is often relatively higher (200-400/μL) than in B21.0-B21.2.


8. Screening

In persons with HIV, persistent (2 weeks or longer) painless lymphadenopathy, B symptoms (fever, night sweats, weight loss), pruritus, or unexplained fatigue requires a biopsy to exclude lymphoma (including Hodgkin lymphoma). At regular HIV follow-up visits, a physical examination including body weight, lymph nodes, and spleen size is recommended. Confirmation of mediastinal and intra-abdominal lymphadenopathy by chest and abdominal CT is performed when symptoms are present.


9. Diagnosis

Confirmation of Hodgkin lymphoma: Identification of Reed-Sternberg cells (giant multinucleated cells, owl-eye nucleoli) on excisional lymph node biopsy. Immunophenotype: CD30+, CD15+, CD20- (mostly), PAX5 weakly positive. EBV association confirmed by EBV EBER ISH. Histologic classification: nodular sclerosis (NScHL), mixed cellularity (McHL), lymphocyte-depleted (LdHL, the most aggressive in HIV), lymphocyte-predominant (NLPHL). Staging: PET-CT (whole body), bone marrow biopsy, blood tests (CBC, LDH, ESR, albumin). Apply the Ann Arbor/Cotswolds staging classification.


10. Treatment

The standard treatment for HIV-associated Hodgkin lymphoma is ABVD (Adriamycin·bleomycin·vinblastine·dacarbazine) chemotherapy. It is combined with ART, with attention to drug interactions. Bleomycin-induced pulmonary toxicity may act additively with HIV pulmonary complications (PCP, etc.), so monitoring is needed. DLCO follow-up testing is performed during chemotherapy cycles. In advanced stage (III/IV), the BEACOPP regimen is applied with caution in immunocompromised patients with HIV because of its high toxicity. In relapsed/refractory Hodgkin lymphoma, brentuximab vedotin (anti-CD30 ADC) is effective. Autologous stem cell transplantation (ASCT) can be performed in chemotherapy-sensitive relapsed patients when CD4 is 200/μL or higher. Bone marrow support with G-CSF and TMP-SMX PCP prophylaxis are essential.


11. Prognosis

In the era of ART plus chemotherapy, the complete remission rate of HIV-associated Hodgkin lymphoma is about 70-80% and the 5-year overall survival rate is about 50-70%. This is lower than the 5-year survival rate of non-HIV Hodgkin lymphoma (~85%), but greatly improved compared with the pre-ART era (~30%). Known poor prognostic factors include Ann Arbor stage IV, lymphocyte-depleted histologic type, accompanying B symptoms, bone marrow involvement, elevated LDH, CD4 <200/μL, age >45 years, and ECOG performance status >1. HIV-associated MCD has high mortality without treatment, but the 5-year survival rate has improved to about 70-80% with the combination of rituximab ± chemotherapy and ART.


12. Prevention

HIV suppression and CD4 maintenance through ART is the most realistic prevention that reduces the risk of all HIV-associated lymphohematopoietic malignant neoplasms, including Hodgkin lymphoma. Prophylactic antiviral therapy for EBV-associated lymphoproliferative disease (ganciclovir, valganciclovir) is used in some post-transplant patients, but evidence for preventing HIV-associated Hodgkin lymphoma has not been established. To prevent MCD, avoiding HHV-8 exposure (safe sexual practices in HHV-8 seropositive patients with HIV) is recommended. Regular lymph node examination and monitoring of abnormal blood counts in persons with HIV help early detection.


13. References

  1. Olszewski AJ, Castillo JJ. Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy. AIDS. 2016;30(5):787-796. DOI: 10.1097/QAD.0000000000000985. PMID: 26684818.

  2. Montoto S, Shaw K, Okosun J, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;30(33):4111-4116. DOI: 10.1200/JCO.2011.41.4193. PMID: 23091107.

  3. Carbone A, Vaccher E, Gloghini A. Hematologic cancers in individuals infected by HIV. Blood. 2016;128(8):1029-1041. DOI: 10.1182/blood-2016-04-712745. PMID: 27418640.

  4. Gérard L, Galicier L, Boulanger E, et al. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. AIDS. 2003;17(1):81-87. DOI: 10.1097/00002030-200301030-00011. PMID: 12478073.

  5. Bohlius J, Schmidlin K, Costagliola D, et al. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy. Antivir Ther. 2009;14(8):1065-1074. PMID: 20032543.

  6. Powles T, Matthews G, Bower M. AIDS related systemic non-Hodgkin's lymphoma. Sex Transm Infect. 2000;76(5):335-341. DOI: 10.1136/sti.76.5.335. PMID: 11141852.

  7. Kaplan LD. HIV-associated lymphoma. Best Pract Res Clin Haematol. 2012;25(1):101-117. DOI: 10.1016/j.beha.2012.01.005. PMID: 22409826.

  8. Stebbing J, Gazzard B, Douek DC. Where does HIV live? N Engl J Med. 2004;350(18):1872-1880. DOI: 10.1056/NEJMra030740. PMID: 15115833.

  9. Bower M, Collins S, Cottrill C, et al. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med. 2008;9(6):336-388. DOI: 10.1111/j.1468-1293.2008.00608.x. PMID: 18564137.

  10. Silverberg MJ, Lau B, Achenbach CJ, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015;163(7):507-518. DOI: 10.7326/M14-2768. PMID: 26167721.